男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
  Home>News Center>World
         
 

Potential HIV/AIDS vaccine gets more tests
(Agencies)
Updated: 2005-01-25 20:51

NEWARK, N.J. - A potential HIV/AIDS vaccine developed by Merck & Co. that uses synthetic genes to prepare cells to fight the deadly virus is moving into the second stage of testing.

An approved vaccine would be about a decade away if the trial and a third study are successful, said officials with the international coalition that is collaborating on the work.

"It is the most promising candidate that we've seen so far," said Sarah B. Alexander, associate director of the coalition, known as the HIV Vaccine Trials Network, or HVTN. She cautioned, however, "something better could come along tomorrow."

Volunteers began enrolling last month for the Phase II study, which will eventually give the potential vaccine's three doses to 1,500 people in North and South America, the Caribbean and Australia, the network and Whitehouse Station-based drug maker announced Monday.

The study is using male and female volunteers aged 18 to 45 of diverse racial groups who are at high risk for contracting HIV. Participants will receive counseling about how to reduce their risk of HIV infection, Alexander said.

About a dozen companies and organizations worldwide are attempting to develop an AIDS vaccine. Of the 10 associated with HVTN, the Merck candidate is the first to reach Phase II testing, Alexander said.

Of the two that reached Phase III, the final stage before certification is sought, one was deemed unsuccessful in 2000, and another, led by the U.S. Department of Defense, is enrolling volunteers, she said.

The Merck candidate — the MRKAd5 HIV-1 gag/pol/nef, or trivalent, vaccine — is designed to persuade the defenders of each cell, called "killer T cells," to attack HIV when the virus enters the cell. Other vaccines generate an antibody response.

The potential vaccine uses the virus of a common cold, modified so it cannot reproduce or cause people to catch a cold, to transport three synthetically produced HIV genes to the cells.

"We give the body enough of the virus so it can recognize it and create an immune response," but not enough to infect a person, Alexander said.

The Phase I study of the possible vaccine, involving about 1,000 people, "generated strong and durable cellular immune responses against HIV," Merck spokeswoman Janet Skidmore said.

Seattle-based HVTN is funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the US Department of Health and Human Services, and comprises more than 25 research institutions worldwide.

Merck shares fell 51 cents, or 1.7 percent, to close at $29.85 in Monday trading on the New York Stock Exchange. The stock, which has fallen sharply since Merck withdrew its Vioxx drug from the market amid safety concerns, has traded in a 52-week range of $25.60 to $49.33.



 
  Today's Top News     Top World News
 

China's GDP grows 9.5% in 2004, higher than forecasts

 

   
 

Revision of law to upgrade mine safety

 

   
 

FM says released men to fly back soon

 

   
 

Myanmar nabs drug lord, sends him back

 

   
 

China seeks to curb corruption in big SOEs

 

   
 

Bank officials flee after US$120m go missing

 

   
  Potential HIV/AIDS vaccine gets more tests
   
  Stampede at Hindu procession kills 150
   
  11 policemen killed in Baghdad clashes
   
  UN: World needs the will to stop genocide
   
  Iraq forces arrest top al-Qaida lieutenant
   
  Torture still routine in Iraqi jails: report
   
 
  Go to Another Section  
 
 
  Story Tools  
   
  Related Stories  
   
Shanxi to test blood sellers for HIV
   
Checking mother-to-child HIV transmission
   
India to step up AIDS fight, launch media campaign
   
Boosting rights of HIV victims
   
Thai-Chinese anti-HIV drug 89% effective
   
HIV pregnant women to be treated free
   
HIV infection rates unchanged in US
  News Talk  
  Are the Republicans exploiting the memory of 9/11?  
Advertisement
         
主站蜘蛛池模板: 大安市| 神农架林区| 南康市| 根河市| 文水县| 浠水县| 桦川县| 克什克腾旗| 龙陵县| 济宁市| 嘉荫县| 和静县| 东山县| 奇台县| 余干县| 历史| 大港区| 南阳市| 陆丰市| 莱西市| 会同县| 无棣县| 始兴县| 漠河县| 冕宁县| 开远市| 体育| 隆安县| 南溪县| 寿阳县| 福海县| 突泉县| 玛沁县| 德钦县| 湖南省| 夏津县| 凤台县| 海晏县| 巴林左旗| 沙河市| 行唐县| 安阳县| 上思县| 梁平县| 泾源县| 大渡口区| 敖汉旗| 阿图什市| 巫溪县| 银川市| 都江堰市| 郓城县| 宁城县| 遵义县| 峨眉山市| 瑞昌市| 尉犁县| 乌审旗| 资中县| 江门市| 二连浩特市| 观塘区| 顺平县| 丹东市| 藁城市| 伊春市| 东乡县| 娄烦县| 库车县| 安徽省| 股票| 平南县| 胶南市| 合川市| 五大连池市| 宜兴市| 保山市| 吐鲁番市| 赣州市| 乐陵市| 新巴尔虎左旗| 龙井市|